|
Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR. |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda |
Speakers' Bureau - celgene; Janssen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen (Inst); Seagen (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Juno Therapeutics; Sanofi; Takeda |
Research Funding - Amgen (Inst); Celgene (Inst); Janssen (Inst); Sanofi (Inst) |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag |
Consulting or Advisory Role - Celgene; Janssen-Cilag; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen-Cilag |
|
|
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Janssen (Inst); La Jolla Pharma (Inst); Novartis (Inst) |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
David Samuel DiCapua Siegel |
Stock and Other Ownership Interests - Celularity |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Karyopharm Therapeutics; Merck; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Takeda |
Research Funding - Celgene (Inst) |